Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) Research & Development (2020 - 2025)

Silo Pharma (SILO) has disclosed Research & Development for 6 consecutive years, with $306005.0 as the latest value for Q4 2025.

  • Quarterly Research & Development fell 71.55% to $306005.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2025, down 6.23% year-over-year, with the annual reading at $2.2 million for FY2025, 8.75% down from the prior year.
  • Research & Development hit $306005.0 in Q4 2025 for Silo Pharma, down from $543615.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.1 million in Q4 2024 to a low of -$649250.0 in Q4 2022.
  • Historically, Research & Development has averaged $262515.6 across 5 years, with a median of $254459.0 in 2023.
  • Biggest YoY gain for Research & Development was 7468.61% in 2021; the steepest drop was 545.89% in 2021.
  • Year by year, Research & Development stood at -$177225.0 in 2021, then crashed by 266.34% to -$649250.0 in 2022, then surged by 151.9% to $336965.0 in 2023, then skyrocketed by 219.24% to $1.1 million in 2024, then crashed by 71.55% to $306005.0 in 2025.
  • Business Quant data shows Research & Development for SILO at $306005.0 in Q4 2025, $543615.0 in Q3 2025, and $717247.0 in Q2 2025.